0.35
+0.0056(+1.62%)
Currency In USD
| Previous Close | 0.35 |
| Open | 0.36 |
| Day High | 0.37 |
| Day Low | 0.34 |
| 52-Week High | 1.54 |
| 52-Week Low | 0.23 |
| Volume | 410,790 |
| Average Volume | 857,522 |
| Market Cap | 27.64M |
| PE | -0.86 |
| EPS | -0.41 |
| Moving Average 50 Days | 0.51 |
| Moving Average 200 Days | 0.69 |
| Change | 0.01 |
If you invested $1000 in Cue Biopharma, Inc. (CUE) since IPO date, it would be worth $30.15 as of January 14, 2026 at a share price of $0.351. Whereas If you bought $1000 worth of Cue Biopharma, Inc. (CUE) shares 5 years ago, it would be worth $27.54 as of January 14, 2026 at a share price of $0.351.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cue Biopharma Announces Pricing of $10 Million Public Offering
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment
Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs®Novel therapeutic approach is designed to enable in vivo expansion and ac
Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates
GlobeNewswire Inc.
Sep 29, 2025 1:00 PM GMT
Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company Cu